Kamada Ltd. (KMDA)

Market Cap	513.41M +29.6%
Revenue (ttm)	180.46M +12.1%
Net Income	20.20M +39.7%
EPS	0.35 +40.0%
Shares Out	57.69M
PE Ratio	25.43
Forward PE	17.62
Dividend	$0.45 (5.06%)
Ex-Dividend Date	Mar 23, 2026

Volume	128,835
Open	8.78
Previous Close	8.70
Day's Range	8.78 - 9.05
52-Week Range	5.54 - 9.35
Beta	0.30
Analysts	Strong Buy
Price Target	14.00 (+57.3%)
Earnings Date	Mar 11, 2026

About KMDA

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM f...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 420
• Stock Exchange: NASDAQ
• Ticker Symbol: KMDA
• Website: https://www.kamada.com

Financial Performance

In 2025, Kamada's revenue was $180.46 million, an increase of 12.12% compared to the previous year's $160.95 million. Earnings were $20.20 million, an increase of 39.66%.

Analyst Summary

According to 2 analysts, the average rating for KMDA stock is "Strong Buy." The 12-month stock price target is $14.0, which is an increase of 57.30% from the latest price.

Price Target

$14.0

(57.30% upside)

Analyst Consensus: Strong Buy